StudyFinder

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

567 Study Matches

HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.

To see how ziltivekimab taken once monthly versus placebo, both added to standard of care, in reducing the risk of cardiovascular death and heart failure events in participants with heart failure iwht mildly reduced or preserved ejection fraction and systemic inflammation.

Return for on site visits 14 times, participate in 6 phone calls, complete questionnaires, blood samples taken at each on-site visit, electrocardiogram completed on 5 visits, injection of study medication.

approximatley $1,120

Yes
 

John Boehmer
HSHVIResearchCoordinators@pennstatehealth.psu.edupsu.edu 717-531-5967
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05636176
STUDY00022895
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
diagnosis of decompensated heart failure
age 18 years or above

Exclusion Criteria:
participation in other clinical study
unstable medical therapy for heart failure
active hepatitis C
pregnant females or females not using effective contraceptive
Heart & Vascular
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

LUX-Dx Heart Failure Sensors in an Insertable Cardiac Monitor System Clinical Study (LUX-Dx TRENDS)

The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer added heart failure diagnostic features. Patients will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell the study doctor if any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if they have been treated with an IV medication for heart failure in the emergency room, urgent care or clinic.

The purpose of this voluntary research study is to collect measurements of related heart function using an insertable cardiac monitor (ICM) in heart failure patients. Commercially available ICMs are used for the detection of abnormal heart rhythms and long-term monitoring. The ICM does not provide therapy, but for this study has various sensors which offer addedheart failure diagnostic features. You will be required to undergo the investigational implantable cardiac defibrillator, attend 6 clinical visits, agree to wear a mobile monitor which is similar to a cell phone with a downloaded application named myLUX, tell your study doctor if you have any planned or unplanned visits to the hospital for any reason, admission to the hospital for heart failure, and/or if you have been treated with an IV medication for your heart failure in the emergency room, urgent care or your clinic.

$250

Yes
 

John Boehmer
HSHVIResearchCoordinators@pennstatehealth.psu.edupsu.edu 717-531-5967
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04790344
STUDY00017092
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Able to use patient mobile app to transmit device data
>18 years of age

Exclusion Criteria:
Currently implanted with any other active electronic medical device
Undergone a heart transplant
Currently enrolled in another investigational study
Pregnant or plans to become pregnant
Diagnosed with amyloidosis or hypertrophic cardiomyopathy
Heart & Vascular
Approved device(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The effects of creatine supplementation on neurocognitive function of college students of differing levels and types of physical activity

This study design is a survey that collects information about students' active level and supplement use, with an emphasis on creatine. The difference between contact and non-contact athletes will be examined, in addition to people who are considered inactive/low activity. This will help provide information of how physical activity related supplementation use affects cognition in different populations, with varying amounts of neurotrauma.

All participants will complete a digital survey that provides information about their dietary supplementation and physical activity habits. As part of the survey, participants will be allowed to indicate their interest and availability to come to a laboratory setting to complete a brief batter of neurocognitive tests.

Yes
 

Semyon Slobounov
Bogdan Ivanov - at bmi5063@psu.edu or 617-327-4064
Kinesiology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023261
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older

Exclusion Criteria:
Under 18 years of age
Has had concussion in last 3 months
Food & Nutrition, Sports Medicine
Survey(s)
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Intraparticipant speaking rate differences within and across sessions

The purpose of this study is to assess if healthy adults speak at a consistent speaking rate when asked to read a standard passage or answer an open ended prompt.

There will be 2 visits that each take approximately 20 minutes. We will meet in person or via Zoom. At each visit you will be asked to read three paragraphs and answer some open ended questions/prompts.

No
 

Nicole Etter
Nicole Etter - at oppal@psu.edu
Communication Sciences and Disorders (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023863
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
English-speaking
Hearing and cognition within functional limits to complete speaking tasks

Exclusion Criteria:
Currently seeking treatment for speech or voice concerns
History of neurologic disease, injury, or event including traumatic brain injury, stroke, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease, etc.
Language & Linguistics
Not applicable
I'm interested
Share via email

Exploring the Concreteness Effect in Expressive and Receptive Language Measures in Healthy Aging as a Comparison for Persons with Aphasia

The concreteness effect is the finding that individuals are faster and more efficient at processing concrete words (e.g., "dog") than abstract words (e.g., "wisdom"). The study will investigate the presence and strength of the concreteness effect in neurologically intact older adults. This data will be used as a control comparison for a group of people with aphasia, a language disorder that commonly results from left hemisphere stroke.

Participants will be asked to complete language and cognition tests that measure attention, memory, problem solving, and language processing on the computer. Participants will be asked to complete two Zoom sessions, each lasting approximately 1.5 hours.

30

No
 

Anna Serrichio
Anna Serrichio - at acs36@psu.edu
Division of Graduate Studies (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023820
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Native English Speaker
At least a high school education
40 years of age or older
Access to device with keyboard and internet connection to participate in Zoom sessions

Exclusion Criteria:
History of neurological, developmental, or psychiatric disorders
Below 40 years of age
Language & Linguistics
Not applicable
I'm interested
Share via email

PSCI 22-132 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

The purpose of this voluntary research study is to evaluate potential new anticancer to treat people with tumors similar to yours. This study will provide information about the safety, the ability of your body to accept the study drug(s), the amount of study drug(s) and/or break-down products in your blood, and your body’s reaction to the study drug(s). Participants will be required to take study medication, have blood drawn, and have imaging tests such as CT, MRI, ECG, MUGA, ECHO, and bone scans.

Participants in the expansion stage will receive study treatment, imaging exams (ECHO, MUGA, ECG, CT, MRI, bone scans), blood draws, tumor assessments, and tumor tissue samples.

Yes
 

Monika Joshi
PSCI-CTO at PSCI-CTO@pennstatehealth.psu.edu or 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05176483
SITE00001372
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Cytologically or histologically confirmed solid tumor that is unresectable, locally advanced or metastatic:
For all Expansion Cohorts except Cohort 3 (mCRPC): Measurable disease per RECIST
For Expansion Cohorts only: Archival tumor tissue material, if available, or fresh tumor tissue if it can be safely obtained.
Recovery to baseline or ≤ Grade 1 CTCAE v5 from AE(s) related to any prior treatments unless AE(s) are deemed clinically nonsignificant by the Investigator and/or stable on supportive therapy.
Age 18 years or older on the day of consent

Exclusion Criteria:
Prior treatment with XL092, nivolumab, ipilimumab, or relatlimab with the following exceptions, which are found in the protocol
Cohort 2 (ccRCC 2L), Cohort 3 (mCRPC), Cohort 5 (UC), Cohort 9 (NSCLC, 2L+), and Cohort 10 (CRC, 2L+): Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.
For Cohort 3 (mCRPC): Receipt of abiraterone within 1 week; cyproterone within 10 days; or receipt of flutamide, nilutamide, bicalutamide, enzalutamide, or other androgen receptor inhibitors within 2 weeks before first dose of study treatment.
Receipt of any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before first dose of study treatment.
Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Sound Symbolism and Aphasia

Sound symbolism is the idea that the sound of a word alone can convey its meaning. Aphasia is a language impairment, occurring most often as a result of a stroke. There is some evidence that sound-symbolic language is preserved in stroke patients. Studies in this protocol will investigate the extent to which this is so, and whether sound-symbolic language could be a rehabilitation strategy for aphasia.

We will ask you to listen to real words and non-words and make judgements about them. We may also ask you to complete some tests of language ability. The total time commitment may be up to four hours but will be split into two sessions.

Amount varies depending on the study

Yes
 

Krishnankutty Sathian
Josh Dorsi - at jdorsi@pennstatehealth.psu.edu
Neurology (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00022919
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be aged 18 or older
Must have English as your first language
Must have normal or corrected-to-normal vision
Must report normal hearing
May have a recent diagnosis of aphasia following a stroke

Exclusion Criteria:
Self-reported hearing difficulty
Bilingual persons may be excluded from some studies
Minors under the age of 18
Language & Linguistics
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Neurobehavioral mechanisms of social and non-social risky decision making.

The purpose of this study is to understand the neural and behavioral mechanisms subserving social and non-social risky decision making.

There will be one in-person lab visit where you will play a decision-making game, while having an fMRI scan.

$31.25

Yes
 

Nina Lauharatanahirun
Nina Lauharatanahirun - at nina.lauhara@psu.edu
Biomedical Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023716
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
Able to read and speak English
Normal to corrected vision in order to see a computer screen clearly
No history of head injury
No MRI contraindications

Exclusion Criteria:
Claustrophobia
History of head injury
Had an event where loss of consciousness > 10 minutes
Weighs more than 300 pounds
Does not read and speak English
Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

A PHASE 1B OPEN-LABEL/ PHASE 2 DOUBLE-BLIND PLACEBO-CONTROLLED STUDY FOR PHARMACODYNAMIC ACTIVITY, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF KAN-101 IN PATIENTS WITH CELIAC DISEASE-A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease

At this time, there is no treatment available for celiac disease diagnosis. The study is designed to test safety, tolerability and pharmacokinetics of KAN-101 to treat celiac disease diagnosis. We will participate only in the Part B study portion. Part B is a Phase 2, double-blind, placebo-controlled, parallel design study to characterize the biomarker response (plasma IL-2) in peripheral blood following gluten challenge, safety, tolerability, and pharmacokinetics (how does drug move in the body) of KAN-101 in adult participants (18 to 70 years inclusive) with histology-confirmed celiac disease. Participants will be randomized 1:1:1:1, where one arm is placebo, and other arms are different drug doses. The study consists of a screening period to determine eligibility to participate, a run-in phase where participants are gluten-challenged for one day, a treatment phase where participants will receive a seven-days treatment, and observation period lasting 358 days where participants will have a post-dose gluten challenge on Day 15, and three other time-points. The study aims to enroll 120 subjects across all sites. Participants will be asked to come for the clinic visit, to have gluten challenged done in the clinic, and treatment infusions in the clinic. There are two follow-up visits planned. The participants will have required EGD w/biopsy, and will be offered optional EGD biopsy study, that collects specimens at two time points. All participants will have a blood work done to access eligibility for participation, and to test for drug PK and biomarkers in the response of the treatment. They will also have EKG and physical examinations, vital signs checked during the clinic visits. They will complete questions for patient reported symptoms. Eligible women participants will be tested for pregnancy, and contraception will be discussed for both male and female participants.

Participants will be asked to come to the clinic visits for the screening, gluten challenge, treatment visits and follow up. During the visits, participants will have blood tests done to determine eligibility for the study, or the test how the drug moves through the body and whether it works to dampen the celiac disease symptoms. The patients will have EGD with biopsies procedure done in the endoscopy suite, and they will be offered optional biopsies study. The gluten challenge will consist of drinking a glass of water containing 9g pre-prepared gluten challenge mix. The participants will be observed for four hours. The treatment is done via infusion in the clinic over 30-minutes,and observed for four hours after that. The participants will have to come in for three treatment visits within seven days (days 1, 4, and 7).

$975

Yes
 

Kofi Clarke
Zvjezdana (Stella) Chroneos - at zchroneos1@pennstatehealth.psu.edu or 717-531-8259
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05574010
STUDY00022990
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
subject is aged 18 to 70 years
positive celiac serology and histology
followed gluten free diet for more than a year

Exclusion Criteria:
have refractory celiac
have wheat allergy
have hypersensitivity to gluten
active GI disease
have Type 1 diabetes
Digestive Systems & Liver Disease
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 23-099 NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancerand an Oncotype Recurrence Score ≤ 25 (OFSET)

To determine if chemotherapy added to ovarian suppression and endocrine therapy is better than endocrine therapy and ovarian supression alone.

Subjects will be required to keep all study appointments, take the medications as required, have an annual mammogram, inform the study of any over the counter medications they may be taking.

Yes
 

Monali Vasekar
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05879926
STUDY00023629
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Female patients must be ≥ 18 years of age.
Patients must be premenopausal
The patient must have an ECOG performance status of ≤ 2
Patients may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy.
Patients may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy.

Exclusion Criteria:
Definitive clinical or radiologic evidence of metastatic disease.
pT4 tumors, including inflammatory breast cancer.
History of ipsilateral or contralateral invasive breast cancer.
Life expectancy of < 10 years due to co-morbid conditions in the opinion of the investigator.
Cancer
Approved drug(s)
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

PSCI 22-142 A Randomized, Open-label, Phase 3 Study of Sacituzumab GovitecanVersus Treatment of Physician’s Choice in Patients With HormoneReceptor-Positive (HR+)/Human Epidermal Growth Factor Receptor2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

This trial is to compare the effects of sacituzumab govitecan versus physician's choice in the treatment of breast cancer

Potential participants will be expected to come to all study visits, complete questionnaires, take the medication as prescribed by the study doctor, report any changes in medications of symptoms while on the trial.

Yes
 

Cristina Truica
PSCI-CTO@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05840211
STUDY00023127
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Assigned male or female at birth, 18 years of age or older (or minimum age according to country-specific requirements), able to understand and give written informed consent.
Must have adequate tumor tissue sample preferably from locally recurrent or metastatic site, either in a formalin-fixed, paraffin-embedded block or newly sectioned, unstained slides for HER2 status and other biomarker assessments.
Documented evidence of HR+ metastatic breast cancer (mBC)
Documented evidence of HER2− status
Documented PD by computed tomography (CT) or magnetic resonance imaging

Exclusion Criteria:
Progressive disease within 6 months of completing (neo)adjuvant chemotherapy.
Previously HER2+
Locally advanced mBC (Stage IIIc) in patients who are candidates for curative intent therapy at the time of study enrollment
Current enrollment in another clinical study
Treatment with definitive radiation within 2 weeks prior to the first dose of study drug
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Moderate to Severe Hidradenitis Suppurativa

This study is a placebo-controlled study testing the effectiveness and safety of a new drug (izokibep) in adults with hidradenitis suppurativa (HS). HS is a condition where painful skin lesions occur, most often in places on the body where there is friction (ex: armpits, under the breasts, buttocks, and groin). These lesions can drain and scar and will often reoccur.

For this study, participants will come to the study site about 17 times over approximately 59 weeks. During these visits, there will information about medical history and medications collected as well as demographic information, physical and skin exams, vital signs, blood and urine lab testing, ECGs, a chest x-ray, questionnaires, and a daily diary.

Yes
 

Joslyn Kirby
Dermatology Clinical Trials - at dermatologyclinicaltrials@pennstatehealth.psu.edu or 717-531-5136
Dermatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05905783
SITE00001430
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of HS for at least 6 months
HS in at least 2 body sites
Willingness to follow study rules and instructions of study staff

Exclusion Criteria:
History of active IBD
Chronic pain not associated with HS
History of HIV
Skin Conditions
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Early Identification in Older Adults of Risks to Sleep Health, Movement, and Cognition Using Ecological Methods

This proposal is a prospective study in which we will collect both subjective and objective quantitative data from older adults residing in independent living retirement communities, microlongitudinally (~1wk). Comprehensive measures of sleep health, cognition, and movement will be collected at community residences. The first phase of this project will recruit local, State College area adults over 70 residing in independent living facilities (e.g., Foxdale Village and The Village at Penn State). A second phase of data collection will extend to community-based older adults in rural parts of Centre and nearby counties.With this prospective, microlongitudinal information we will evaluate the characteristics of sleep predictive of daytime cognitive and neurobehavioral function and use those conclusions to inform nonpharmacologic, preventative interventions for older adults.

After consent, there will be 6 study visits at either Penn State University Park campus or at the participant's personal residence. Study participation lasts about 1 week.Participants wear non-invasive ambulatory watch-like activity monitors throughout (both day and night) the week. Participants complete electronic surveys and cognitive tests 6 times daily, with additional surveys at study conclusion.Sleep and daytime brain and heart activity are recorded (without video) using non-invasive clinical-type wire sensors applied to the face, head, and chest. Wires are worn on the face, head, and chest throughout the first two study nights. Wires are worn on the head and chest throughout the first two study days. There is not a sleep intervention in this study. We are collecting data about the typical sleep health of older adults and its relation to cognitive health.

$350

Yes
 

Orfeu Buxton
Margeaux Gray - at ecosleep@psu.edu or 814-863-5800
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00011786
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
>=50 and <91 years of age
Resident of PA, Centre County region
Living without functional assistance
Able to walk unassisted for at least 5min

Exclusion Criteria:
Previous participants are not eligible
Evidence of cognitive impairment (will be tested)
Men's Health, Sleep Management, Women's Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Genomic Profiling of Urothelial Cancers Study

The objective of this protocol is to study urothelial cancer with detailed health history, tumor and/or normal tissues available for genomic sequencing to study cancers in the bladder, upper urinary tract, and urethra. There will be 3 groups of subjects in this study:1)Urothelial cancer patients receiving care at Penn State Health2)Relatives of patients with urothelial cancer3)High risk-cohort of individuals with family history of urothelial cancers or inherited cancer syndromes (such as Lynch syndrome) candidates for urothelial cancer screening evaluation

All subjects will be asked to fill out questionnaires to assess risk factors for urinary cancer and document family history of cancer. You will be asked to provide a blood sample and urine sample for genetic testing. Patients with urothelial cancer will be asked to allow us to test leftover tissue from a past or future biopsy to test cancer and/or normal cells for certain mutations. We may also ask you for a saliva sample, cheek swab, skin biopsy, or nail clippings for comparison.

Yes
 

Hong Truong
UrologyResearch@pennstatehealth.psu.edu
Urology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00021468
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
personal or family history of urothelial cancer
personal or family history of bladder cancer

Exclusion Criteria:
Cancer other than urothelial cancer
Cancer
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps – The BiRCh Study

The purpose of this study is to find out if the experimental drug (brensocatib) improves symptoms of Chronic Rhinosinusitis Without Nasal Polyps and is safe. Study treatments include the study drug and mometasone furoate nasal spray (referred to as mometasone). The study drug will either be brensocatib (“active” drug that contains “real” drug) or placebo (looks like brensocatib but does not have any “real” drug in it). Mometasone will be taken by all participants throughout the study as routine care.

If you choose to participate in the study, the following main activities and procedures are required.•Complete questionnaires asking about your chronic rhinosinusitis symptoms and quality of life•Measure the amount of air you can breathe in through both sides of your nose (nasal airflow)•Electrocardiogram (ECG) and vital signs•Physical examination, including examinations of your mouth and skin•Provide blood and urine samples•Sinus computed tomography (CT) scan•Attend 9 study visits•Nasal endoscopy

Unknown at this time

Yes
 

Timothy Craig
Kara Grim - at kgrim@pennstatehealth.psu.edu or 717-531-4513
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06013241
STUDY00023061
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 18 to 75
Participants who have at least a 12-week history before Screening Visit of Chronic Rhinosinusitis without nasal polyps
Received a course of antibiotics or steroids to treat symptoms of Chronic Rhinosinusitis within 1 year or previous surgery for Chronic Rhinosinusitis

Exclusion Criteria:
Diagnosis of nasal polyps
Diagnosis of Cystic Fibrosis or Primary Ciliary Dyskinesia
Scheduled sinus surgery at any time during the study or have had nasal surgery within 4 weeks of the first study visit
Participants with seasonal allergic rhinitis whose symptoms occur during the treatment period of the study
Current smoker
Allergies
Experimental drug compared to a placebo/”sugar pill”
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Pilot study examining adherence to and efficacy of the quitSTART smoking cessation smartphone application

The goal of this pilot study is to collect preliminary information about the effectiveness of a smoking cessation app called quitSTART, which is a product of Smokefree.gov created by the Tobacco Control Research Branch at the National Cancer Institute. The app is available to the public for download at no cost. The aims of the project are: 1) to measure how participants respond to the app and how they use it during an attempt to quit smoking; and 2) receptivity and adherence rates to the app; 2) to examine whether participants reduce or discontinue smoking while using the app.

The study is designed to test the efficacy of a smoking cessation smartphone app and has three parts. For the first part, participants are asked to watch an orientation video about the study, fill out questionnaires, and watch a video tutorial explaining how to use a smartphone app. Then, for the second part of the study, participants are asked to use the smoking cessation app to help them with their quit attempt for 30 days. Finally, for the third part of the study, participants are asked to complete an exit survey about their experience using the app after 30 days.

$20

No
 

Stephen Wilson
Stephen Wilson - at sjw42@psu.edu
Psychology (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00021797
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be 21-65 years old
Must smoke cigarettes everyday
Must own and regularly use a smartphone
Must be planning a quit attempt within the next month
Must be willing to use a smartphone app to assist them during a quit attempt

Exclusion Criteria:
Meet criteria for current dependence on a substance other than nicotine
Previously used the quitSTART smartphone app
Smoking, Vaping, Nicotine and Tobacco
Survey(s)
I'm interested
Share via email

Sex and race differences in exercise pressor reflex under blood flow restriction condition

The purpose of this voluntary research study is to test the effects of exercise on reduction in blood flow to exercising muscle.

You will be asked to participate in one visit to perform handgrip exercise and foot exercises with, and without a blood pressure cuff inflated on your arm and leg. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate, blood flow and muscle oxygenation.

You will receive $25 per hour for your participation in this research study

Yes
 

Jian Cui
Cheryl Blaha - at cblaha@pennstatehealth.psu.edu or 717-531-1605
Heart and Vascular Institute (HERSHEY)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023505
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Males and Females 21-80 years of age
All races and ethnicities welcome
Are fluent in written and spoken English
Healthy status as defined by history and physical
blood pressure that is within a safe range (<150/100)

Exclusion Criteria:
less than 21 years of age or greater than 80 years of age
Pregnant or nursing woman
Current smoker
Any chronic diseases (heart, lung, neuromuscular disease or diabetes)
High blood pressure
Heart & Vascular
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Precision mEdicine and Adoptive Cellular tHerapy for the treatment of recurrent neuroblastoma and newly diagnosed diffuse intrinsic pontine glioma (DIPG)

This study is being done to learn if a vaccine made in the laboratory from your tumor and your immune cells is safe to give to you to treat your tumor. It is believed that the body’s immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to kill the tumor. In this research study, we will use your tumor and immune cells from your blood to make a vaccine that we hope will stimulate your T-cells to kill tumor cells and leave your normal cells alone.

You will need routine (standard of care) testing for your tumor, as well as research tests and procedures including further analysis of your tumor sample, generation and review of a personalized genetic report, and procedures to collect certain cells for different infusions and creation of specialized cellular vaccines. You will then be offered and placed on a treatment plan. As a subject in this study you will remain in this study until you complete vaccine therapy as long as you have no disease progression or unless you need to come off study for another reason.

Yes
 

Valerie Brown
Suzanne Treadway - at streadway@pennstatehealth.psu.edu or 717-531-3097
Pediatrics: Hematology/Oncology (HERSHEY)
 

All
All
This study is NOT accepting healthy volunteers
NCT04837547
STUDY00023080
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Neuroblastoma that has either returned or has not responded to standard therapies or a diagnosis of Diffuse Intrinsic Pontine Glioma (DIPG).
For Neuroblastoma must be >12 months and ≤ 30 years of age
For DIPG must be ≥ 3 years and ≤ 30 years of age

Exclusion Criteria:
Absence of tumor on biopsy specimen or a diagnosis other than NBL or glioma on biopsy
Known autoimmune or immunosuppressive disease or human immunodeficiency virus infection
Cancer
Prefer not to display
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

A Phase 3 Open-label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics, and Efficacy ofCSL312 (Garadacimab) in the Prophylactic Treatment ofHereditary Angioedema in Pediatric Subjects 2 to 11 Years ofAge

This is a voluntary research study that will help us see if the study medication, CSL312, is safe to use in children 2-11 years of age. The research study will also help to see if the medication works to prevent HAE attacks in this age group.

Attend 8 to 9 visits to the study center. Provide personal information about the child participating in the study and complete electronic diaries (eDiaries). The child participating in the study will have physical exams, vital signs, and blood/urine tests completed. The study medication will be given via injection.

Yes
 

Timothy Craig
Kara Grim - at kgrim@pennstatehealth.psu.edu or 717-531-4513
Medicine: Pulmonary, Allergy and Critical Care (HERSHEY)
 

All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT05819775
STUDY00023499
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged 2 to 11 years
Diagnosis of Hereditary Angioedema Type 1 or Type 2
Two or more Hereditary Angioedema attacks within the last 6 months or the 6 months before starting a preventative medication

Exclusion Criteria:
Any preplanned surgeries or procedures during the study period
Receiving any other experimental drug
Diagnosis of any other form of angioedema
Allergies
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Emotion dynamics and alcohol use in NIAAA-defined recovery from alcohol use disorder

This study uses a baseline assessment and 28 days of ecological momentary assessment to examine the association of emotion dynamics to craving and alcohol use among people in the first year of cessation of heavy drinking and remission from DSM-5 AUD.

There will be one in person visit. Participants will be asked to complete baseline questionnaires. After the baseline assessment, participants will complete 28 days of daily diary questions on their cell phone. A prompt will be sent to the phone 3 times per day. It should take 5 minutes (15 minutes total/day) to complete the questions.

189

Yes
 

Brad Linn
Brad Linn - at blinn1@pennstatehealth.psu.edu or 717-531-0003, ext=321641
Family and Community Medicine (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
STUDY00024054
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Aged between 18-68
Have a history of a previous (AUD) in the past year
Live within commuting distance of the Penn State Clinical Research Center

Exclusion Criteria:
Acute psychosis
Bipolar disorder
Cognitive impairment
Active drug use disorder other than nicotine or cannabis dependence
Lack of sufficient familiarity with the English language to comprehend recruitment and consent procedures
Men's Health, Addiction & Substance Abuse, Mental & Behavioral Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Impact of fermented pulses on inflammation and the gut microbiota

The purpose of this study is to investigate whether fermenting pulse foods (e.g. beans, chickpeas, lentils, peas, etc.) changes their effects on the gut microbiome and inflammation. Participants will eat provided meals of either fermented or unfermented pulses, providing blood and fecal samples at the beginning of the study and after two weeks of eating meals containing each of the pulse types.

The study lasts 8 weeks. 2 weeks where you do not consume any of the test food (pulses such as chickpeas, lentils, peas or beans), 2 weeks of consuming the first type of the provided meals, 2 weeks without consuming any of the test foods, 2 weeks consuming the second type of provided meals. There will be five in person visits, one at the beginning to provide consent and then one at the end of each 2 week section. At three of these visits a fecal sample will be collected, blood will be drawn and a dietary survey completed.

300

Yes
 

Darrell Cockburn
Darrell Cockburn - at dwc30@psu.edu or 814-863-2950
Food Science (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT06134076
STUDY00023162
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
healthy
18-65

Exclusion Criteria:
antibiotic use in the past month
BMI >24.9
Taking any medication for diabetes or weight management
Pregnant
Allergies to meal components
Food & Nutrition
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Effect of color, lighting, and music on visual perception, cognition, and emotion

To comprehensively examine the psychological effects of abstract lighting patterns on individuals' emotional states, cognitive performance, and overall well-being. Secondly, the study aims to explore the intriguing connection between music-color synesthesia and the perception of lighting conditions.

Participants will complete cognitive tests and subjective evaluations

Yes
 

Dorukalp Durmus
Dorukalp Durmus - at alp@psu.edu
Architectural Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023417
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
good visual acuity
normal color vision
adults between 18 and 40

Exclusion Criteria:
not synesthetic
metal allergy
Vision & Eyes
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Infection threat and social decision-making using fMRI

The purpose of this study is to test how social decisions are affected by possible risk of infection. We aim to examine the neural and behavioral mechanisms underlying how choices in a risky social decision-making situation can be influenced by viewing images of infection threat (e.g., person with runny nose) vs. images of neutral scenes or other threatening scenes.

Participants will come to the research site for a one-time visit. They will complete brief questionnaires, followed by playing a social decision-making game while undergoing fMRI scanning.

$35.42

Yes
 

Nina Lauharatanahirun
Nina Lauharatanahirun - at nina.lauhara@psu.edu
Biomedical Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023786
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
English speaking
Does not suffer from claustrophobia
Does not have contraindications to MRI scanning
Does not weigh more than 300 pounds

Exclusion Criteria:
Normal to corrected vision in order to see a computer screen clearly
Cannot speak English
Suffers from claustrophobia
Has contraindications to MRI scanning
Weighs more than 300 pounds
COVID-19, Neurology
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Lighting, familiarity, decision making and risk taking

The effect of familiarity of an space on visual and lighting perceptions, and the effect of lighting conditions on risk taking and decision making will be investigated

Participants will wear sensors and complete survey that consists of decision making questions and subjective evaluations of architectural spaces.

Yes
 

Dorukalp Durmus
Dorukalp Durmus - at alp@psu.edu
Architectural Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023419
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Normal color vision
Good visual acuity

Exclusion Criteria:
Visual impairments (e.g., low vision, color deficiency)
Metal allergy
Mental & Behavioral Health, Vision & Eyes
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

PSCI 23-008: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status ACR-368-201/GOG-3082

This trial will be looking at patients with OncoSignature positive and negative tumors using the treatment of the study drug in combination with ultra low dose gemcitabine.

If you are in Arm 1, you will receive ACR-368 as a single intravenous (in the vein) infusion over approximately 60 minutes twice during a 4-week period, on Days 1 and 15. This entire 4-week period is called a cycle. If you are in Arm 2, you will receive gemcitabine and ACR-368 as two separate intravenous (in the vein) infusions. The gemcitabine infusion will last approximately 30 minutes and the ACR-368 infusion will last approximately 60 minutes. •Biopsy Sample and OncoSignature® Status•Archived Tumor Sample and Genomic Information•Physical Exam•Pregnancy Test if applicable•Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan•Blood Sampling for CA-125 (Ovarian carcinoma only)

Yes
 

Monika Joshi
psci-cto@pennstatehealth.psu.edu 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT05548296
STUDY00023067
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Subjects who are 18 years of age or older at time of consent.
Subject must have histologically confirmed, locally advanced (ie, not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.
Subject must have at least 1 measurable lesion per RECIST v1.1 criteria (by local Investigator)
Subject must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated after signed informed consent.
Subject must have an estimated life expectancy of longer than 3 months.

Exclusion Criteria:
Subject has a history of major surgery within 4 weeks of Screening
Subject has a history of clinically meaningful coagulopathy, bleeding diathesis.
Subject had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug.
Subject with known symptomatic brain metastases requiring > 10 mg/day of prednisolone (or its equivalent).
Subject has taken a prior cell cycle CHK1 inhibitor, including ACR-368.
Cancer
Experimental drug compared to an approved drug
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

Personality Pathology in Youth

In this study, we hope to better understand the neural mechanisms underlying risk for personality disorders in adolescent youth. Understanding who is at risk for personality disorders early in development is important in order to develop preventative interventions.

Youth participants and their parent will be required to attend one in-person visit at our lab in Hershey, PA where youth participants will complete two computer tasks while EEG data are collected. Youth participants will also complete questionnaires and a peer-interaction task with another peer their age. Parents will complete questionnaires and an interaction task with their child. Youth participants will complete remote surveys via a survey app for two weeks after the visit. This study includes 4 follow-up appointments (once every 6 months) which can be completed in-person or remotely via a Microsoft Teams meeting. These follow-up appointments will consist of a parent-child interaction task and surveys for parent and youth participants.

$300

Yes
 

Dara Babinski
Julia Leslie - at abc@pennstatehealth.psu.edu or 717-531-0003, ext=285968
Psychiatry and Behavioral Health (HERSHEY)
 

All
Younger than 18 years old
This study is also accepting healthy volunteers
STUDY00023682
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children ages 10-13 and their parent
Current or past history of a mental health disorder OR no history of mental health disorder
Fluent in English

Exclusion Criteria:
Children under 10 or over 13
Youth or parent not fluent in English
Youth with intellectual or development disabilities
Youth with schizophrenia, bipolar disorder, or other psychotic disorders
Mental & Behavioral Health
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,

The impact of structural racism and discrimination on chronic pain in Black or African American older adults: Biopsychosocial mechanisms

This study is trying to understand more about factors that cause pain in people who have had experiences of discrimination.

Study Requirements:-Two visits - each ~3 hours to the Milton S. Hershey Medical Center-Visit 1: computer questionnaires, sensory testing, mobility testing, blood draw-Visit 2: questionnaires, 1-hr MRI with painful but tolerable heat and sounds-At home questionnaires online between visits or added to second visit -Video and vital sign monitoring during some parts-Option to wear a smartwatch between visits for additional compensationStudy Compensation:-$175 with the option of up to $225-Visit 1: $100-Visit 2: $75-Smartwatch option: $50-Reimbursement for parking, transportation, or free ride via Uber Health-Souvenir copy of your brain scan

$225 + $25/visit transportation

Yes
 

Elizabeth Losin
Elizabeth Losin - at erl5393@psu.edu or 814-863-7256
Biobehavioral Health (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
SITE00001393
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Musculoskeletal pain in lower back or knee for at least 3 months
Age 45 and up
Identify as Black or African American
Able to perform experimental tasks
Speak, read, and understand English

Exclusion Criteria:
Unable to tolerate MRI (e.g., claustrophobia)
Metal in body that is not safe for MRI
Previous abnormal MRI
Pregnancy
Muscle & Bone, Pain Management
I'm interested
Share via email
Show 2 locations

Study Locations

Hide all locations
Location Contacts
Harrisburg, PA ,
Hershey, PA ,

Using grip force as a measure of fear in humans during a robot guided haunted house scenario

The objectives of the study are to determine whether grip force is related to participants’ fear and whether touch feedback from a robot can effectively communicate risk in a simulated high stress environment. We hypothesize that grip force increases in stressful situations like walking through a haunted house. Like in a real haunted house, people often find comfort in holding hands with someone as they walk through. In this study, a participant walks through a virtual haunted house.

There will be one in person visit. Participant will wear VR equipment and chest heart rate monitor. They will hold a virtual robot's hand and walk through a VR haunted house environment until it is over. They will then answer a brief survey.

15

Yes
 

Alan Wagner
Savanna Spazak - at szs685@psu.edu or 724-705-4893
Aerospace Engineering (UNIVERSITY PARK)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
STUDY00023827
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
An adult over the age of 18
Must not be suffering from anxiety disorders and/or panic attacks.
Must not be suffering from any known heart conditions.
Must not, to your knowledge, be prone to nausea when experiencing VR

Exclusion Criteria:
Under 18
Motion sickness caused by VR
Heart problems
Anxiety disorder
prone to nausea in VR
Not applicable
I'm interested
Share via email
Show 1 location

Study Locations

Hide all locations
Location Contacts
State College, PA ,

Investigating Post-Pandemic Impacts on the Mobility of Transportation Disadvantaged Groups

In this study, we're investigating how the COVID-19 pandemic has influenced the way people who face challenges in transportation—perhaps due to limited access or resources—get around. We're curious about any changes they made during the pandemic, like using different modes of transportation or adjusting their travel habits. Additionally, we're exploring whether these changes might stick around even after the pandemic. It's all about understanding the impact of the pandemic on the travel choices of those who already face transportation difficulties and what this might mean for the future.

There will be a questionnaire that should take approximately 15 minutes to complete.

No
 

Nikhil Menon
Catherine Suria - at cms8094@psu.edu or 717-805-0599
Science, Engineering and Technology (HARRISBURG)
 

All
18 year(s) or older
This study is also accepting healthy volunteers
NCT00000000
STUDY00024149
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Low-income: Personal income less than $35,000/yr.
Do not own or lease private vehicle
Disability that impacts mobility
Rely on government assistance (state or federal)

Exclusion Criteria:
Non low-income: personal income over $35,000/yr
Private vehicle owners
COVID-19
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients with Nonalcoholic Steatohepatitis

This study will be a pilot study to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously confirmed in patients with cirrhosis,(1) in patients with Nonalcoholic Steatohepatitis (NASH)

El-Fit NASH (Nonalcoholic Steatohepatitis) is a 9-week intervention trial for patients with NASH. Our goal is to evaluate the workability, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program. The El-FIT application allows for participants to access to a library of guided workouts. All patients will be asked to complete a screening visit that includes a physical exam, height, and weight measurements &amp; surveys. Participants will be asked to download the EL-Fit NASH application and use it for 8 weeks. In addition to using the application, participants will be asked to complete 3 check-in phone calls through-out the 8 weeks.

Yes
 

Jonathan Stine
Stine Laboratory at StineLaboratory@pennstatehealth.psu.edu or 717-531-0003, ext=320222
Medicine: Gastroenterology and Hepatology (HERSHEY)
 

All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT06195943
STUDY00022771
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
Evidence of NASH
Posission of a Smart Phone

Exclusion Criteria:
Active cardiac Symptoms
Active or recent participation in exercise training program within the last 90 years
Active or recent weight-loss supplement use within the last 90 days
Active illicit substance use
Cancer that is active
Digestive Systems & Liver Disease, Sports Medicine
Not applicable
I'm interested
Share via email
See this study on ClinicalTrials.gov
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,